Product update

Everolimus for preventing organ rejection

Everolimus has been licensed for the prevention of organ rejection after kidney, heart or liver transplant. For this indication, the medicine is available in 0.25mg, 0.5mg and 0.75mg tablets called Certican (Novartis). For kidney and heart transplant, Certican tablets should be used in combination with ciclosporin for microemulsion and corticosteroids. For liver transplant, it should be used in combination with tacrolimus and corticosteroids.

Citation: The Salvadore DOI: 10.1211/PJ.2015.20068496

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Adverse Drug Reactions

    A practical guide to the drug reactions that affect particular organ systems, and the management of these reactions.


Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.

купить аккумулятор Varta

viagra ou cialis